Metadoxine improves the three- and six-month survival rates in patients with severe alcoholic hepatitis

World Journal of Gastroenterology

Volumn 21, Issue 16, 2015, Pages 4975-4985

  Higuera De La Tijera, Fátima ^a   Servín Caamaño, Alfredo I ^a   Serralde Zúñiga, Aurora E ^b   Cruz Herrera, Javier ^a   Pérez Torres, Eduardo ^a   Abdo Francis, Juan M ^a   Salas Gordillo, Francisco ^a   Pérez Hernández, José L ^a  

^a HOSPITAL GENERAL DE MÉXICO   (Mexico)

^b Fundacion Mexicana para la Salud AC   (Mexico)

Author keywords

Alcohol abstinence; Alcoholic hepatitis; Metadoxine; Survival

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; METADOXINE; PENTOXIFYLLINE; PREDNISONE; SODIUM; UREA; DRUG COMBINATION; DRUGS USED IN THE TREATMENT OF ADDICTION; GLUCOCORTICOID; PYRIDOXINE; PYROGLUTAMIC ACID;

ACUTE KIDNEY FAILURE; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL PERITONITIS; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; EPIGASTRIC BURNING; ESOPHAGUS CANDIDIASIS; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HEPATIC ENCEPHALOPATHY; HUMAN; INTERNATIONAL NORMALIZED RATIO; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; NAUSEA AND VOMITING; NEUTROPHIL; OPEN STUDY; PNEUMONIA; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SODIUM BLOOD LEVEL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; UREA BLOOD LEVEL; URINARY TRACT INFECTION; ALCOHOL ABSTINENCE; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; HEPATITIS, ALCOHOLIC; KAPLAN MEIER METHOD; MEXICO; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME;

ADULT; ALCOHOL ABSTINENCE; ALCOHOL DETERRENTS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HEPATITIS, ALCOHOLIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MEXICO; MIDDLE AGED; PENTOXIFYLLINE; PREDNISONE; PROPORTIONAL HAZARDS MODELS; PYRIDOXINE; PYRROLIDONECARBOXYLIC ACID; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84928405016     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i16.4975     Document Type: Article

References (53)

1. Mathurin P, Mendenhall CL, Carithers RL, Ramond MJ, Maddrey WC, Garstide P, Rueff B, Naveau S, Chaput JC, Poynard T. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002;36:480-487 [PMID: 11943418 DOI: 10.1016/S0168-8278 (01) 00289-6]
2. Parker R, Armstrong MJ, Corbett C, Rowe IA, Houlihan DD. Systematic review: pentoxifylline for the treatment of severe alcoholic hepatitis. Aliment Pharmacol Ther 2013;37:845-854 [PMID: 23489011 DOI: 10.1111/apt.12279]
3. Garrido-García JR, Sánchez-Hernández G, Melchor-López A, Elizalde-Barrera CI, Sánchez-Vargas L. Pentoxifilina versus esteroide en la sobrevivencia a corto plazo en hepatitis aguda alcohólica severa [Article in Spanish]. Med Int Mex 2012;28:227-233
4. Dominguez M, Rincón D, Abraldes JG, Miquel R, Colmenero J, Bellot P, García-Pagán JC, Fernández R, Moreno M, Bañares R, Arroyo V, Caballería J, Ginès P, Bataller R. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol 2008;103:2747-2756 [PMID: 18721242 DOI: 10.1111/j.1572-0241.2008.02104.x]
5. Altamirano J, Higuera-De Latijera F, Duarte-Rojo A, Martínez-Vázquez MA, Abraldes JG, Herrera-Jiménez LE, Michelena J, Zapata L, Perez-Hernández J, Torre A, Gonzáles-González JA, Cardenas A, Dominguez M, Arroyo V, Ginès P, Caballería J, Bataller R. The amount of alcohol consumption negatively impacts short-term mortality in Mexican patients with alcoholic hepatitis. Am J Gastroenterol 2011;106:1472-1480 [PMID: 21556041 DOI: 10.1038/ajg.2011.141]
6. Voican CS, Perlemuter G, Naveau S. Mechanisms of the inflammatory reaction implicated in alcoholic hepatitis: 2011 update. Clin Res Hepatol Gastroenterol 2011;35:465-474 [PMID: 21571602 DOI: 10.1016/j.clinre.2011.01.017]
7. Seth D, Haber PS, Syn WK, Diehl AM, Day CP. Pathogenesis of alcohol-induced liver disease: classical concepts and recent advances. J Gastroenterol Hepatol 2011;26:1089-1105 [PMID: 21545524 DOI: 10.1111/j.1440-1746.2011.06756.x]
8. Lieber CS. Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis. Alcohol 2004;34:9-19 [PMID: 15670660 DOI: 10.1016/j.alcohol.2004.07.008]
9. Váli L, Blázovics A, Fehér J. [The therapeutic effect of metadoxine on alcoholic and non-alcoholic steatohepatitis]. Orv Hetil 2005;146:2409-2414 [PMID: 16398154]
10. Higuera-De La Tijera F, Servín-Caamaño AI, Cruz-Herrera J, Serralde-Zúñiga AE, Abdo-Francis JM, Gutiérrez-Reyes G, Pérez-Hernández JL. Treatment with metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis. Ann Hepatol 2014;13:343-352 [PMID: 24756009]
11. Theodossi A, Eddleston AL, Williams R. Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis. Gut 1982;23:75-79 [PMID: 7035299 DOI: 10.1136/gut.23.1.75]
12. Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med 2009;360:2758-2769 [PMID: 19553649 DOI: 10.1056/NEJMra0805786]
13. Caballería J, Parés A, Brú C, Mercader J, García Plaza A, Caballería L, Clemente G, Rodrigo L, Rodés J. Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double-blind, placebo-control trial. Spanish Group for the Study of Alcoholic Fatty Liver. J Hepatol 1998;28:54-60 [PMID: 9537864]
14. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11:R31 [PMID: 17331245 DOI: 10.1186/cc5713]
15. Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology 2008;48:2064-2077 [PMID: 19003880 DOI: 10.1002/hep. 22605]
16. Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007;56:1310-1318 [PMID: 17389705 DOI: 10.1136/gut.2006.107789]
17. Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009;49:2087-2107 [PMID: 19475696 DOI: 10.1002/hep. 22853]
18. Córdoba J. New assessment of hepatic encephalopathy. J Hepatol 2011;54:1030-1040 [PMID: 21145874 DOI: 10.1016/j.jhep. 2010.11.015]
19. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007;46:922-938 [PMID: 17879356 DOI: 10.1002/hep. 21907]
20. Ruíz-Zavala A, Gil-Rojas N, Higuera-De La Tijera M. Response to prednisone in Mexican patients with alcoholic hepatitis in a period of four years in the Hospital General de Mexico [Abstract]. Ann Hepatol 2012;11:602
21. Flores YN, Yee HF, Leng M, Escarce JJ, Bastani R, Salmerón J, Morales LS. Risk factors for chronic liver disease in Blacks, Mexican Americans, and Whites in the United States: results from NHANES IV, 1999-2004. Am J Gastroenterol 2008;103:2231-2238 [PMID: 18671818 DOI: 10.1111/j.1572-0241.2008.02022.x]
22. De BK, Gangopadhyay S, Dutta D, Baksi SD, Pani A, Ghosh P. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World J Gastroenterol 2009;15:1613-1619 [PMID: 19340904 DOI: 10.3748/wjg.15.1613]
23. Park SH, Kim DJ, Kim YS, Yim HJ, Tak WY, Lee HJ, Sohn JH, Yoon KT, Kim IH, Kim HS, Um SH, Baik SK, Lee JS, Suk KT, Kim SG, Suh SJ, Park SY, Kim TY, Jang JY. Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: a randomised, non-inferiority, open trial. J Hepatol 2014;61:792-798 [PMID: 24845609 DOI: 10.1016/j.jhep. 2014.05.014]
24. Forrest E, Mellor J, Stanton L, Bowers M, Ryder P, Austin A, Day C, Gleeson D, O'Grady J, Masson S, McCune A, Patch D, Richardson P, Roderick P, Ryder S, Wright M, Thursz M. Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial. Trials 2013;14:262 [PMID: 23958271 DOI: 10.1186/1745-6215-14-262]
25. Addolorato G, Ancona C, Capristo E, Gasbarrini G. Metadoxine in the treatment of acute and chronic alcoholism: a review. Int J Immunopathol Pharmacol 2003;16:207-214 [PMID: 14611722]
26. Calabrese V, Carlino S, Chinnici V, De Bernardis E, Rizza V. Metadoxine modulates the absorption, metabolism and elimination kinetics of ethanol. Riv Ital Alcol 1986;5:44-49
27. Díaz Martínez MC, Díaz Martínez A, Villamil Salcedo V, Cruz Fuentes C. Efficacy of metadoxine in the management of acute alcohol intoxication. J Int Med Res 2002;30:44-51 [PMID: 11921498 DOI: 10.1177/147323000203000107]
28. Gutiérrez-Ruiz MC, Bucio L, Correa A, Souza V, Hernández E, Gómez-Quiroz LE, Kershenobich D. Metadoxine prevents damage produced by ethanol and acetaldehyde in hepatocyte and hepatic stellate cells in culture. Pharmacol Res 2001;44:431-436 [PMID: 11712874 DOI: 10.1006/phrs.2001.0883]
29. Calabrese V, Calderone A, Ragusa N, Rizza V. Effects of Metadoxine on cellular status of glutathione and of enzymatic defence system following acute ethanol intoxication in rats. Drugs Exp Clin Res 1996;22:17-24 [PMID: 8839633]
30. Felicioli R, Saracchi I, Flagiello AM, Bartoli C. Effects of pyridoxine-pyrrolidon-carboxylate on hepatic and cerebral ATP levels in ethanol treated rats. Int J Clin Pharmacol Ther Toxicol 1980;18:277-280 [PMID: 7192694]
31. Baldacci M, Catalani R, Bartoli C, Mura U. Effects of pyridoxinepyrrolidonecarboxylate on hepatic adenosine triphosphate levels in rats. Boll Soc Ital Biol Sper 1982;58:1643-1649 [PMID: 7168788]
32. Calabrese V, De Bernardis E, Rizza V. [Metadoxine in the control of oxidative stress caused by acute and chronic ethanol poisoning]. Boll Soc Ital Biol Sper 1986;62:1357-1363 [PMID: 3828134]
33. Calabrese V, Randazzo G, Ragusa N, Rizza V. Long-term ethanol administration enhances age-dependent modulation of redox state in central and peripheral organs of rat: protection by metadoxine. Drugs Exp Clin Res 1998;24:85-91 [PMID: 9675549]
34. Malhotra PS, Singh BR, Narotam B, Kaur KP. A study of metadoxine in alcoholic liver disease [Abstract]. J Assoc Physicians India 2005;53:352-353
35. Vedrova NN, Gnezdilova NIu. [Metadoxyl in combined treatment of alcohol damage to the liver]. Klin Med (Mosk) 2001;79:56-58 [PMID: 11496744]
36. Fehér J, Váli L, Blázovics A, Lengyel G. The Beneficial effect of metadoxine (pyridoxine-pyrrolidone-carboxylate) in the treatment of fatty liver diseases. CEMED 2009;3:65-76 [DOI: 10.1556/CEMED.3.2009.1.6]
37. Ceni E, Mello T, Galli A. Pathogenesis of alcoholic liver disease: role of oxidative metabolism. World J Gastroenterol 2014;20:17756-17772 [PMID: 25548474 DOI: 10.3748/wjg.v20.i47.17756]
38. Tbahriti HF, Meknassi D, Moussaoui R, Messaoudi A, Zemour L, Kaddous A, Bouchenak M, Mekki K. Inflammatory status in chronic renal failure: The role of homocysteinemia and proinflammatory cytokines. World J Nephrol 2013;2:31-37 [PMID: 24175263 DOI: 10.5527/wjn. v2.i2.31]
39. Malaponte G, Bevelacqua V, Fatuzzo P, Rapisarda F, Emmanuele G, Travali S, Mazzarino MC. IL-1beta, TNF-alpha and IL-6 release from monocytes in haemodialysis patients in relation to dialytic age. Nephrol Dial Transplant 2002;17:1964-1970 [PMID: 12401854 DOI: 10.1093/ndt/17.11.1964]
40. Higuchi T, Fukuda N, Yamamoto C, Yamazaki T, Oikawa O, Ohnishi Y, Okada K, Soma M, Matsumoto K. The influence of uremic serum on interleukin-1beta and interleukin-1 receptor antagonist production by peripheral blood mononuclear cells. Ther Apher Dial 2006;10:65-71 [PMID: 16556139 DOI: 10.1111/j.1744-9987.2006.00346]
41. Orlowski M, Meister A. The gamma-glutamyl cycle: a possible transport system for amino acids. Proc Natl Acad Sci USA 1970;67:1248-1255 [PMID: 5274454 DOI: 10.1073/pnas.67.3.1248]
42. Merrill AH, Henderson JM. Diseases associated with defects in vitamin B6 metabolism or utilization. Annu Rev Nutr 1987;7:137-156 [PMID: 3300730 DOI: 10.1146/annurev. nu.07.070187.001033]
43. Garau B, Fadda F, Melis F, Gelso E, Gessa GL. Metadoxine (pyrrolidone carboxylate of pyridoxine) antagonizes the locomotorstimulatory effect of ethanol in mice. Alcohol Alcohol 1992;27:501-504 [PMID: 1476554]
44. Wang T, Zhu D, Xu X, Xu Y. The amelioration of AH by abstinence and the attenuation of oxidative stress. Hepatogastroenterology 2012;59:73-76 [PMID: 21940381 DOI: 10.5754/hge11259]
45. Leggio L, Kenna GA, Ferrulli A, Zywiak WH, Caputo F, Swift RM, Addolorato G. Preliminary findings on the use of metadoxine for the treatment of alcohol dependence and alcoholic liver disease. Hum Psychopharmacol 2011;26:554-559 [PMID: 22095793 DOI: 10.1002/hup. 1244]
46. Guerrini I, Gentili C, Nelli G, Guazzelli M. A follow up study on the efficacy of metadoxine in the treatment of alcohol dependence. Subst Abuse Treat Prev Policy 2006;1:35 [PMID: 17176456 DOI: 10.1186/1747-597X-1-35]
47. Pár A. [Treatment of alcoholic liver diseases. Abstinence, nutritional support, drug therapy, liver transplantation]. Orv Hetil 2000;141:827-833 [PMID: 10817009]
48. Rizzo A, Breda A, Moretto F, Pace M, Dotta C, Gelso E, Sanzuol F, Tossani C. [Therapeutic use of metadoxine in chronic alcoholism. Double blind study of patients in a department of general medicine]. Clin Ter 1993;142:243-250 [PMID: 8482064]
49. Bono G, Sinforiani E, Merlo P, Belloni G, Soldati M, Gelso E. Alcoholic abstinence syndrome: short-term treatment with metadoxine. Int J Clin Pharmacol Res 1991;11:35-40 [PMID: 1678735]
50. Manor I, Ben-Hayun R, Aharon-Peretz J, Salomy D, Weizman A, Daniely Y, Megiddo D, Newcorn JH, Biederman J, Adler LA. A randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy, safety, and tolerability of extended-release metadoxine in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2012;73:1517-1523 [PMID: 23290324 DOI: 10.4088/JCP.12m07767]
51. Manor I, Newcorn JH, Faraone SV, Adler LA. Efficacy of metadoxine extended release in patients with predominantly inattentive subtype attention-deficit/hyperactivity disorder. Postgrad Med 2013;125:181-190 [PMID: 23933905 DOI: 10.3810/pgm.2013.07.2689]
52. Manor I, Rubin J, Daniely Y, Adler LA. Attention benefits after a single dose of metadoxine extended release in adults with predominantly inattentive ADHD. Postgrad Med 2014;126:7-16 [PMID: 25295645 DOI: 10.3810/pgm.2014.09.2795]
53. Altamirano J, Miquel R, Katoonizadeh A, Abraldes JG, Duarte-Rojo A, Louvet A, Augustin S, Mookerjee RP, Michelena J, Smyrk TC, Buob D, Leteurtre E, Rincón D, Ruiz P, García-Pagán JC, Guerrero-Marquez C, Jones PD, Barritt AS, Arroyo V, Bruguera M, Bañares R, Ginès P, Caballería J, Roskams T, Nevens F, Jalan R, Mathurin P, Shah VH, Bataller R. A histologic scoring system for prognosis of patients with alcoholic hepatitis. Gastroenterology 2014;146:1231-9.e1-6 [PMID: 24440674 DOI: 10.1053/j.gastro.2014.01.018]